![]() |
市場調查報告書
商品編碼
1831859
2025-2033 年寵物癌症治療市場報告(依療法、動物種類、癌症類型、最終使用者和地區)Pet Cancer Therapeutics Market Report by Therapy, Animal Species, Cancer Type, End User, and Region 2025-2033 |
2024年,全球寵物癌症治療市場規模達3.202億美元。展望未來, IMARC Group預計到2033年,該市場規模將達到6.648億美元,2025-2033年期間的複合年成長率(CAGR)為8.03%。寵物擁有率的提高、人類與動物之間聯繫的加深、獸醫學和研究的進步,以及人們對寵物癌症治療的可用性和益處的認知不斷提高,是推動市場發展的主要因素。
寵物癌症治療是專門用於診斷、治療和管理動物(尤其是犬貓)癌症的醫療手段和藥物。與人類癌症治療類似,這些療法可能包括化療、放射治療、免疫療法、標靶治療和安寧療護。獸醫腫瘤科醫師運用這些療法來治療寵物的各種癌症,並改善其生活品質。隨著獸醫學的不斷進步,寵物癌症治療的可用性和有效性不斷提高,使寵物主人能夠為他們被診斷患有癌症的愛寵獲得全面而富有愛心的護理。
隨著寵物擁有量的增加以及人類與動物之間聯繫的加深,寵物主人越來越願意投資先進的醫療手段,包括癌症治療,以確保其寵物的健康,這將在預測期內刺激市場的成長。此外,由於診斷能力的提高和壽命的延長,寵物癌症的發生率不斷上升,這增加了對有效和專業治療的需求。除此之外,獸醫腫瘤學和研究領域的許多進步,包括開發更有針對性和創新性的寵物癌症療法,都催化了市場的成長。此外,寵物主人對寵物癌症治療的可用性和益處的認知不斷提高,促進了早期發現和干涉,從而推動了市場的成長。此外,專業獸醫腫瘤中心的建立以及獸醫和人類腫瘤學家之間日益增多的合作,提高了寵物癌症治療的可及性和專業性,也促進了市場的成長。
增加寵物擁有量和人與動物之間的聯繫
寵物飼養數量的成長以及人類與動物之間聯繫的加深已成為寵物癌症治療市場的重要驅動力。隨著越來越多的家庭開始接納寵物,這些伴侶動物被廣泛視為珍貴的家庭成員。這種情感連結培養了寵物主人強烈的責任感,確保他們毛茸茸夥伴的福祉和健康。因此,寵物主人越來越願意投資先進的癌症治療方法,以對抗疾病並提高寵物的生活品質。寵物主人尋求為寵物提供最好的護理,這導致對能夠減輕寵物痛苦並延長其壽命的有效癌症治療方法的需求不斷成長。
獸醫腫瘤學的進展
近年來,由於技術進步和研究突破,獸醫腫瘤學領域取得了顯著進展。診斷技術的改進使得癌症的早期檢測和準確率得以提升,使獸醫能夠及時進行治療。此外,對寵物癌症生物學理解的不斷加深,為標靶治療、免疫療法和新型治療模式的研發打開了大門。獸醫腫瘤學家如今擁有更豐富的癌症治療工具,能夠根據每隻寵物的具體情況制定個人化的照護計畫。這些進步為那些心愛寵物面臨癌症診斷的寵物主人帶來了希望,並鼓勵他們探索和選擇先進且有效的癌症療法。
獸醫保健支出不斷成長
人們對寵物的認知從單純的動物夥伴轉變為珍貴的家庭成員,這導致了獸醫醫療保健支出模式的顯著轉變。如今,寵物主人比以往任何時候都更願意投入大量資金來確保寵物的健康和長壽。人們對現有癌症治療方案的認知日益加深,並渴望提供盡可能優質的護理,這推動了寵物癌症治療支出的成長。寵物主人願意投資最新、最有效的癌症治療方法,以對抗疾病,並改善他們毛茸茸夥伴的整體健康和幸福感。獸醫醫療保健支出的激增進一步推動了寵物癌症治療市場的發展,為寵物癌症治療方案的研究、創新和開發創造了機會。
The global pet cancer therapeutics market size reached USD 320.2 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 664.8 Million by 2033, exhibiting a growth rate (CAGR) of 8.03% during 2025-2033. The increasing pet ownership rates and human-animal bond, advancements in veterinary medicine and research, and growing awareness about the availability and benefits of pet cancer therapeutics are some of the major factors propelling the market.
Pet cancer therapeutics are specialized medical treatments and drugs designed to diagnose, treat, and manage cancer in animals, particularly in dogs and cats. Similar to cancer treatments in humans, these therapeutics may include chemotherapy, radiation therapy, immunotherapy, targeted therapies, and palliative care. Veterinary oncologists administer these therapies to address various types of cancer in pets and improve their quality of life. As advancements in veterinary medicine continue, the availability and effectiveness of pet cancer therapeutics have increased, allowing pet owners to access comprehensive and compassionate care for their beloved animal companions diagnosed with cancer.
The rising willingness among pet owners to invest in advanced medical treatments, including cancer therapeutics, to ensure the well-being of their animal companions due to the increasing pet ownership and human-animal bond, will stimulate the growth of the market during the forecast period. Moreover, the growing prevalence of cancer in pets, owing to improved diagnostic capabilities and prolonged lifespan has augmented the demand for effective and specialized treatments. Apart from this, numerous advancements in veterinary oncology and research, including the development of more targeted and innovative cancer therapies for pets, have catalyzed the market growth. Additionally, the heightening awareness among pet owners about the availability and benefits of pet cancer therapeutics has led to early detection and intervention, propelling the market growth. Furthermore, the establishment of specialized veterinary oncology centers and the rising collaborations between veterinary and human oncologists that improve the accessibility and expertise in pet cancer care are contributing to the market growth.
Increasing pet ownership and human-animal bond
The rise in pet ownership and the strengthening human-animal bond have become significant drivers in the market for pet cancer therapeutics. As more households welcome pets into their lives, these companion animals are widely considered cherished family members. This emotional connection fosters a deep sense of responsibility among pet owners to ensure the well-being and health of their furry companions. Consequently, there is a growing willingness among pet owners to invest in advanced cancer treatments to combat the disease and enhance the quality of life for pets. Pet owners seek the best possible care for their pets, leading to an increased demand for effective cancer therapeutics that can alleviate suffering and prolong their pets' lives.
Advancements in veterinary oncology
The field of veterinary oncology has witnessed remarkable progress in recent years, owing to technological advancements and research breakthroughs. Improved diagnostic techniques enable early and accurate cancer detection, empowering veterinarians to initiate timely treatment. Moreover, the rise in understanding of cancer biology in pets has opened doors to targeted therapies, immunotherapies, and novel treatment modalities. Veterinary oncologists now have an expanded toolbox of cancer treatments, facilitating the development of personalized care plans tailored to each pet's unique condition. These advancements instill hope in pet owners facing a cancer diagnosis for their beloved animals and encourage them to explore and opt for advanced and effective cancer therapies.
Growing veterinary healthcare expenditure
The changing perception of pets from mere animal companions to valued family members has led to a notable shift in spending patterns on veterinary healthcare. Pet owners today are more willing than ever to allocate substantial financial resources to ensure their pets' well-being and longevity. The growing awareness of available cancer treatment options and the desire to provide the best possible care have driven the increase in expenditure on pet cancer therapeutics. Owners are willing to invest in the latest and most effective cancer treatments to combat the disease and improve the overall health and happiness of their furry companions. This surge in veterinary healthcare spending further propels the pet cancer therapeutics market, creating opportunities for research, innovation, and the development of advanced cancer treatment options for pets.
Chemotherapy dominates the market
Chemotherapy is widely used as a standard treatment for various types of pet cancers. As a potent and systematic approach, chemotherapy targets rapidly dividing cancer cells, inhibiting their growth and spread. Its ability to treat a wide range of cancers, including lymphoma, mast cell tumors, and osteosarcoma, makes it a versatile and essential therapeutic option for veterinary oncologists.
Moreover, advancements in veterinary medicine have led to the development of more targeted and less toxic chemotherapy regimens, reducing adverse effects and improving the overall quality of life for pets undergoing treatment. The increasing prevalence of pet cancer cases, coupled with the growing awareness among pet owners about available treatment options, further contributes to the expansion of the chemotherapy segment.
Dogs hold the largest share in the market
Dogs have a higher susceptibility to various types of cancers, mirroring human conditions. As a popular companion animal, dogs are commonly affected by cancers such as lymphoma, melanoma, and mammary tumors, among others. The similarities in cancer biology and tumor types between dogs and humans make dogs valuable models for studying cancer treatments, leading to advancements in therapeutic approaches that benefit both species. Veterinary oncology research conducted in dogs has resulted in the development of targeted therapies, immunotherapies, and novel treatment modalities that can be translated to human medicine. Furthermore, the strong emotional bond between pet owners and their dogs fosters a willingness to invest in their healthcare, including cancer treatments, thus driving the demand for effective pet cancer therapeutics.
Mast cell cancer represents the most popular type of cancer
Mast cell tumors are one of the most common skin cancers in dogs, affecting various breeds and age groups. Their diverse behavior and variable response to treatments necessitate specialized therapeutics for effective management. Veterinary oncologists are continually researching and developing targeted therapies and immunotherapies specifically tailored to combat mast cell cancer. As a result, advancements in pet cancer therapeutics for mast cell tumors benefit dogs as well as contribute to the broader understanding and treatment of mast cell-related conditions in humans. The increasing awareness among pet owners about the need for early detection and comprehensive treatment options further drives the demand for innovative and efficient pet cancer therapeutics.
Veterinary hospitals and clinical pharmacies account for the largest market share
Veterinary hospitals and clinical pharmacies play a crucial role in driving the pet cancer therapeutics market by serving as key distribution and treatment centers for specialized pet cancer drugs and therapies. These institutions provide a centralized platform for pet owners to access a wide range of cancer treatments, including chemotherapy agents, targeted therapies, and immunotherapies. Veterinary hospitals collaborate with pharmaceutical companies and research institutions to stay updated on the latest advancements in pet cancer therapeutics, offering cutting-edge treatment options to their patients. Clinical pharmacies within these facilities ensure accurate drug dispensing and administration, adhering to precise dosages and treatment protocols. Their expertise in handling pet cancer therapeutics and providing personalized care contributes to improved treatment outcomes and enhances pet owners' confidence in seeking optimal cancer care for their beloved animal companions, ultimately driving the growth of the pet cancer therapeutics market.
North America exhibits a clear dominance in the market
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and Others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and Others) Latin America (Brazil, Mexico and Others), Middle East and Africa. According to the report, North America accounted for the largest market share.
North America held the biggest share in the market since the region has a high prevalence of pet ownership, and there is a strong bond between pet owners and their animals, leading to a greater willingness to invest in their healthcare, including cancer treatment. North America is also at the forefront of advancements in veterinary medicine and oncology research, resulting in the development of innovative and targeted pet cancer therapeutics. Veterinary hospitals and research institutions in the region collaborate closely with pharmaceutical companies to conduct clinical trials and introduce cutting-edge treatments to the market. Additionally, the presence of well-established veterinary healthcare infrastructure and a growing trend of personalized pet care contribute to the demand for specialized and effective cancer therapies. These factors collectively drive the growth of the market for pet cancer therapeutics in North America, making it a leading region in the industry.
The market is experiencing steady growth in recent years as various key players are focusing on the development of targeted therapies and immunotherapies tailored to specific types of pet cancers, aiming to enhance treatment effectiveness and reduce side effects. Numerous advancements in precision medicine by leading players have led to the identification of genetic and molecular biomarkers, allowing for personalized treatment approaches. Additionally, novel drug delivery methods, such as nanoparticles and liposomes, are being explored by manufacturers to improve drug stability and enhance tumor penetration. The integration of emerging technologies like artificial intelligence (AI) and machine learning (ML) in pet cancer research is revolutionizing data analysis and accelerating drug discovery processes. We also expect the market to witness new entrants, consolidation of product portfolios, rise in research and development (R&D) initiatives, and increased strategic collaborations to drive healthy competition within the pet cancer therapeutics domain.
Purchase OptionsDiscount
Offer
Single User License29993899